Determining the effects of treatments on vascular disease risk by meta-analyses using individual participant data
Lead Research Organisation:
Medical Research Council
Abstract
This programme of research provides reliable evidence of the effects of treatment with common drugs, such as aspirin, other painkillers (NSAIDs), and statins. Since the effects of commonly used treatments are often modest, but important in terms of their long-term health consequences, studies generally require data on very large numbers of patients. Individual clinical trials on their own on such drugs are too small to assess such effects reliably, so we use a method called meta-analysis to examine aggregated data from all relevant trials. This involves collaborating with other scientists worldwide who have undertaken such trials, securing their agreement to provide the individual patient data, and then analysing this large amount of individual patient level data from the various trials to develop a more detailed understanding of the effects of particular treatments. For example, our previous work has helped to provide guidance on which people benefit from aspirin and statins, and has also provided useful information about the risks of NSAIDs. The results of these collaborative studies are widely used to guide doctors in the use of drug treatments internationally, and also help to identify which areas of research are required to tackle outstanding clinical questions.
Technical Summary
This programme of research determines the effects of common treatments, such as non-steroidal anti-inflammatory drugs (NSAIDs) and statins, on the risk of vascular disease, whether as an intended benefit or as an unanticipated hazard, by conducting meta-analyses. We coordinate collaborations of trialists to conduct meta-analyses, using individual participant data contributed by investigators and sponsors, but analysed independently of the funding source of the trials. In each of the various collaborations, the effects and safety of the treatment under study can be assessed more reliably through the use of data from individual participants. In particular, it is possible to examine the effects of treatments on particular outcomes (with broadly similar definitions across different studies), assess possible variation in the effects of treatments in different types of patients, and assess the temporal evolution of treatment effects in relation to drug use. Our previous work has helped to resolve significant uncertainties about the treatment of common conditions in different patient groups. For example, the Antithrombotic Treatment Trialists’ (ATT) Collaboration has shown that, among patients who already have occlusive vascular disease, long-term antiplatelet therapy (e.g. with aspirin) reduces the annual risk of serious vascular event by about a quarter. This typically corresponds to an absolute reduction of about 10-20 per 1000 in the annual incidence of serious vascular events. Against this benefit, the absolute increase in major gastrointestinal or other major extracranial bleeds is about ten times smaller. Hence, for secondary prevention, it is widely agreed that the benefit of aspirin substantially exceeds risk. For primary prevention, however, the balance is less clear because the absolute vascular benefits of aspirin are an order of magnitude lower in this setting than in secondary prevention, and our work has shown that aspirin is not appropriate for primary prevention. Similarly, the Coxib and traditional NSAIDs Trialists’ (CNT) Collaboration has helped quantify the cardiovascular and gastrointestinal risks of non-steroidal anti-inflammatory drugs, which led to changes in drug-labelling for diclofenac in Europe, and the Cholesterol Treatment Trialists’ [CTT] Collaboration has documented the benefits and safety of statin therapy in a wide variety of people, including people at low risk of vascular disease, again influencing guidelines worldwide. Future work will address areas of uncertainty within existing meta-analyses (including, within the CTT for example, analyses of adverse events within trials of statin therapy), as well as tackling new questions, such as the balance of benefit and risk of rt-PA in ischaemic stroke within the Stroke Thrombolysis Trialists’ (STT) Collaboration.
Organisations
- Medical Research Council (Lead Research Organisation)
- University of Nottingham, United Kingdom (Collaboration)
- VU University Medical Center (Collaboration)
- University of Edinburgh, United Kingdom (Collaboration)
- Russells Hall Hospital (Collaboration)
- University of Texas Southwestern Medical Center (Collaboration)
- Nordic School of Public Health (Collaboration)
- Mayo Clinic (Collaboration)
- Tokai University (Collaboration)
- State University of New York (Collaboration)
- University of Paris 13 (Paris North) (Collaboration)
- University of Sydney, Australia (Collaboration)
- New England Research Institute (Collaboration)
- Oslo University Hospital (Collaboration)
- Georgetown University, United States (Collaboration)
- University of Dundee, United Kingdom (Collaboration)
- Sahlgrenska University Hospital (Collaboration)
- Florida Atlantic University (Collaboration)
- Johns Hopkins Medicine (Collaboration)
- University of Rome I (La Sapienza), Italy (Collaboration)
- Rosalind Franklin University of medicine (Collaboration)
- Royal Perth Hospital (Collaboration)
- AstraZeneca plc (Collaboration)
- University Medical Centre Nijmegen (Collaboration)
- Stanford University, United States (Collaboration)
- University of Cagliari, Italy (Collaboration)
- Leiden University Medical Center (Collaboration)
- United States Department of Veterans Affairs (Collaboration)
- Catholic University Medical School (Collaboration)
- Washington University in St. Louis (Collaboration)
- King Fahd Hospital, Saudi Arabia (Collaboration)
- Fred Hutchinson Cancer Research Center (FHCRC) (Collaboration)
- Oxford University Hospitals NHS Trust, United Kingdom (Collaboration)
- Hamilton Health Sciences (Collaboration)
- University of Texas at San Antonio, United States (Collaboration)
- Auckland City Hospital (Collaboration)
- University of Louisville (Collaboration)
- University of North Carolina at Chapel Hill (Collaboration)
- Miguel Servet University Hospital (Collaboration)
- UNLISTED (Collaboration)
- Pfizer Ltd (Collaboration)
- Taipei Veterans General Hospital (Collaboration)
- Firat University (Collaboration)
- Lund University (Collaboration)
- Uni of Texas Health Sci Ctr San Antonio (Collaboration)
- Haukeland University Hospital (Collaboration)
- University Hospital, Josef-Schneider-Str 2, Germany (Collaboration)
- George Institute for Global Health (Collaboration)
- King's College London, United Kingdom (Collaboration)
- University College London, United Kingdom (Collaboration)
- Tripler Medical Army Center, US (Collaboration)
- University of Arizona, United States (Collaboration)
- University Hospital of North Norway (Collaboration)
- University Hospital Cleveland (Collaboration)
- University of Lyon (Collaboration)
- Vall d'Hebron University Hospital (Collaboration)
- Wageningen University & Research (Collaboration)
- Academic Medical Center (Collaboration)
- Massachusetts General Hospital (Collaboration)
- University of Bergen, Norway (Collaboration)
- University of Ottawa, Canada (Collaboration)
- Fondazione IRCCS Policlinico San Matteo (Collaboration)
- University of Ghent, Belgium (Collaboration)
- Sheba Medical Centre (Collaboration)
- Sanofi (Collaboration)
- Bayer (Collaboration)
- Vanderbilt University, United States (Collaboration)
- John Radcliffe Hospital, United Kingdom (Collaboration)
- Italian Auxological Institute (Collaboration)
- Imperial College London, United Kingdom (Collaboration)
- Rikshospitalet , Sogsnsavvsveien (Collaboration)
- Grants Admin Office (Collaboration)
- MAM College of Pharmacology (Collaboration)
- University of Zagreb (Collaboration)
- Johns Hopkins University, United States (Collaboration)
- Cleveland Clinic (Collaboration)
- Antwerp University Hospital (Collaboration)
- University of Gothenburg, Sweden (Collaboration)
- Jacksonville Centre for Clinical Research (Collaboration)
- Statistics Collaborative (Collaboration)
- Tisch Hospital (Collaboration)
- Pharma Clinical (Collaboration)
- University College Dublin, Ireland (Collaboration)
- Boehringer Ingelheim, Germany (Collaboration)
- Harvard University (Collaboration)
- Icahn School of Medicine at Mount Sinai (Collaboration)
- London Health Sciences Centre (Collaboration)
- ANMCO Research Centre (Collaboration)
- Ecological Institute of Caspian Sea (Collaboration)
- University of Toronto (Collaboration)
- St Mary's Hospital, London (Collaboration)
- University of Wuerzburg, Germany (Collaboration)
- Helsinki University Central Hospital (Collaboration)
- University of Pennsylvania, United States (Collaboration)
- Northwestern University (Collaboration)
- Hospital of Psychiatry and Psychotherapy, Germany (Collaboration)
- University of North Texas (Collaboration)
- University of Utah, United States (Collaboration)
- National Taiwan University, Taiwan, Province of China (Collaboration)
- University of Melbourne, Australia (Collaboration)
- Bichat-Claude Bernard Hospital (Collaboration)
- Mitsukoshi Health & Welfare Foundation (Collaboration)
- Royal London Hospital (Collaboration)
- Commission on Human Medicines (CHM) (Collaboration)
- The University of Iowa, United States (Collaboration)
- Mario Negri Institute for Pharmacological Research (Collaboration)
- Rush University Medical Center, United States (Collaboration)
- Cedars-Sinai Medical Center (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Maastricht University (UM) (Collaboration)
- Brigham and Women's Hospital (Collaboration)
- London Sch of Hygiene and Trop Medicine, United Kingdom (Collaboration)
- University of Glasgow, United Kingdom (Collaboration)
- Merck (Collaboration)
- Yale University (Collaboration)
- University of East Anglia, United Kingdom (Collaboration)
- Unité de Recherche en Epidémiologie Nutritionnelle (UREN), Sorbonne-Paris-Cité, UMR Inserm, Paris, France (Collaboration)
- Technical University Dresden, Germany (Collaboration)
- Queen's Medical Centre (Collaboration)
- Erasmus MC (Collaboration)
- Pfizer, United States (Collaboration)
- New York University, United States (Collaboration)
- University of Alabama at Birmingham, United States (Collaboration)
- Royal Brompton Hospital (Collaboration)
- Ulleval University Hospital (Collaboration)
- University of Western Australia, Australia (Collaboration)
- Sasaki Institute (Collaboration)
- Toronto General Hospital (Collaboration)
- University Hospitals Birmingham NHS Foundation Trust, Birmingham (Collaboration)
- Gastrointestinal & Other Cancers Research Group (Collaboration)
- Churchill Hospital (Collaboration)
- Tri-Services General Hospital (Collaboration)
- Catholic University of the Sacred Heart (Collaboration)
- Florey Institute of Neuroscience and Mental Health (Collaboration)
- Regeneron Pharmaceuticals, Inc. (Collaboration)
- Thrombosis Center of Buenos Aires (Collaboration)
- Ogun State University Teaching Hospital (OSUTH) (Collaboration)
- Seoul National University (Collaboration)
- Linkoping University (Collaboration)
- National Cerebral and Cardiovascular Centre (Collaboration)
- Novartis (Collaboration)
- Hennepin County Medical Center (Collaboration)
- National Heart, Lung, and Blood Institute (NHLBI) (Collaboration)
- University Medical Ctr Hamburg-Eppendorf (Collaboration)
- American University of Beirut (Collaboration)
- Mexican Social Security Insitute (IMSS) (Collaboration)
- BC Children's Hospital (Collaboration)
- University of Maryland, United States (Collaboration)
- University of Zaragoza (Collaboration)
- University of Otago, New Zealand (Collaboration)
- Western University (Collaboration)
- Schulthess Clinic (Collaboration)
- McMaster University, Canada (Collaboration)
- Uppsala University (Collaboration)
- Monash University, Australia (Collaboration)
- Tufts University (Collaboration)
- Beijing Huilongguan Hospital (Collaboration)
- University College London Hospital (UCLH) NHS Foundation Trust (Collaboration)
- Wake Forest University, United States (Collaboration)
- Bristol-Myers Squibb (Collaboration)
- Glasgow Royal Infirmary (Collaboration)
- VA Boston Healthcare System (Collaboration)
- Boston Children's Hospital (Collaboration)
- University of Chieti Pescara, Italy (Collaboration)
Publications
Al-Shahi Salman R
(2019)
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial
in The Lancet
Antithrombotic Trialists' (ATT) Collaboration
(2009)
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
in Lancet (London, England)
Armitage J
(2016)
Lessons from the controversy over statins - Authors' reply
in The Lancet
ASCEND Study Collaborative Group
(2018)
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
in The New England journal of medicine
Authors/Task Force Members
(2020)
Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].
in Atherosclerosis
Baigent C
(2011)
Efficacy and safety of more intensive lowering of LDL cholesterol - Authors' reply
in The Lancet
Baigent C
(2009)
Aspirin in the primary prevention of vascular disease - ATT secretariat's reply
in The Lancet
Baigent C
(2016)
Aspirin for Disease Prevention: Public Policy or Personal Choice?
in Annals of internal medicine
Baigent C
(2008)
Selective COX-2 inhibitors: where do we go from here?
in The Lancet
Baigent C
(2010)
Oxford Textbook of Medicine
| Guideline Title | American Diabetes Association indications for statins in diabetes (Diabetes Care 2009; 32: S384-91) |
| Description | American Diabetes Association indications for statins in diabetes |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Recommendation from ADA that all patients with diabetes receive a statin and that the target LDL cholesterol among them should be <2.6 mmol/L |
| Guideline Title | European Guidelines on Cardiovascular Disease Prevention in Clinical Practice |
| Description | European Guidelines on Cardiovascular Disease Prevention in Clinical Practice |
| Geographic Reach | Asia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | ESC clinical guidelines influence the management of cardiovascular disease in both primary and secondary care. |
| Description | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors |
| Geographic Reach | Asia |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Impact | Our 2013 Lancet publication (see below) was cited in the press release as providing the new evidence that resulted in the EMA issuing updated guidance. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 30 May 2013 doi:10.1016/S0140-6736(13)60900-9 |
| URL | http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001816.js... |
| Guideline Title | Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2018. |
| Description | Impact of STT paper Effects of Alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 Trials |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children |
| Description | Impact of STT paper Effects of Alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 Trials |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Acute Inpatient Stroke Care, 6th Edition, Update 2018 |
| Description | Impact of STT paper Effects of alteplase for acute stroke according to criteria defining the EU and US marketing authorizations: Individual-patient-data meta-analysis of randomized trials |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Influenced clinical guidelines |
| Description | MRC Network of Hubs for Trials Methodology Research: Development of novel analysis methods in a systematic meta-analysis allowing indirect comparisons |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | The Vascular Overviews Group which runs various collaborative meta-analyses including the Cholesterol Treatment Trialists' Collaboration, Anti-thrombotic Treatment Trialists' Collaboration and, the more recently set up, Coxib and traditional NSAID Trialists' (CNT) Collaboration has continued its work on several fronts leading to a high profile publication in the Lancet in 2013 on the vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs. A novel element of these analyses was that treatment effects were estimated by comparing the results of trials of a coxib versus placebo and trials of a coxib versus traditional NSAID. The conditions under which such indirect comparisons might be expected to yield valid results were satisfied, since the two sets of trials involved similar doses of coxibs and similar populations, and different studies used the same (high-dose) tNSAID regimens as comparators. This enabled the quantification of the hazards of various NSAIDs which had been substantially uncertain in the past. This work was widely reported in the scientific and lay media. |
| Guideline Title | NICE Guideline (CG181): Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease |
| Description | NICE Guideline: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Stains should be considered for a much wider group of patients, including those with diabetes and chronic kidney disease and if there estimated 10-year risk of cardiovascular disease is 10% or more. |
| URL | http://www.nice.org.uk/guidance/cg181 |
| Description | BHF Centre for Research Excellence |
| Amount | £43,000 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | MRC Training Fellowship |
| Amount | £234,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2008 |
| End | 05/2012 |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | Brigham and Women's Hospital |
| Department | Division of Cardiovascular Medicine |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | Catholic University of the Sacred Heart |
| Department | School of Medicine (UCSC) |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | Florida Atlantic University |
| Department | Charles E. Schmidt College of Science |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | Italian Auxological Institute |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Department | Clinical Gerontology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | Antithrombotic Treatment Trialists' (ATT) Collaboration |
| Organisation | Monash University |
| Department | Department of Epidemiology and Preventive Medicine |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716). ASPREE trial results published September 2018 (see https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803955) |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | Brigham and Women's Hospital |
| Department | Department of Medicine |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | Harvard University |
| Department | Department of Epidemiology |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | Haukeland University Hospital |
| Department | Department of Heart Disease |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | McMaster University |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | Paris 13 University |
| Department | Research Unit on Nutritional Epidemiology, INSERM U557 |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | Radboud University Nijmegen Medical Center |
| Department | Department of Endocrinology |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | Royal Perth Hospital |
| Department | Department of Neurology |
| Country | Australia |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | Stanford University |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | United States Department of Veterans Affairs |
| Country | United States |
| Sector | Public |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | University Hospital of North Norway |
| Department | Department of Heart Disease |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | University of Bergen |
| Department | Institute of Medicine |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | University of North Carolina at Chapel Hill |
| Department | UNC School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | University of Nottingham |
| Department | Division of Epidemiology and Public Health |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | VA Boston Healthcare System |
| Department | Massachusetts Veterans Epidemiology Research and Information Center |
| Country | United States |
| Sector | Public |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cancer Collaboration |
| Organisation | Western University |
| Department | Department of Clinical Neurological Sciences |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual patient data from their randomised trials. |
| Impact | This collaboration has clearly demonstrated the lack of effect of folic acid on vascular outcomes (2010, Archives of Internal Medicine; 170: 1622-31), or cancer incidence (2013, Lancet 381: 23-9). |
| Start Year | 2006 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | Brigham and Women's Hospital |
| Department | Department of Medicine |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | London Health Sciences Centre |
| Department | Department of Neurology |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Department | Department of Nutrition and Public Health Intervention Research |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | Maastricht University (UM) |
| Department | School for Public Health and Primary Care Maastricht |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | McMaster University |
| Department | Population Health Research Institute |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | Unité de Recherche en Epidémiologie Nutritionnelle (UREN), Sorbonne-Paris-Cité, UMR Inserm, Paris, France |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | University of Bergen |
| Department | Department of Global Public Health and Primary Care (IGS) |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | University of Glasgow |
| Department | Institute of Cardiovascular and Medical Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | University of Gothenburg |
| Department | Sahlgrenska Academy |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | University of Otago |
| Department | Department of Human Nutrition |
| Country | New Zealand |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | University of Western Australia |
| Department | School of Medicine and Pharmacology |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | B-Vitamins Cognitive Function Collaboration |
| Organisation | Wageningen University & Research |
| Department | Division of Human Nutrition |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collaboration which has brought together the individual patient data from randomised trials of folic acid supplementation in individuals at increased risk of cardiovascular disease. |
| Collaborator Contribution | Collaborators provide individual level patient data from their randomised trials. |
| Impact | None. |
| Start Year | 2008 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | ANMCO Research Centre |
| Country | Italy |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Auckland City Hospital |
| Country | New Zealand |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Bayer |
| Country | Germany |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Bristol-Myers Squibb |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Churchill Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Erasmus MC |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Fred Hutchinson Cancer Research Center (FHCRC) |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Glasgow Royal Infirmary |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Hamilton Health Sciences |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Harvard University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Hennepin County Medical Center |
| Department | Division of Clinical Epidemiology |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Jacksonville Centre for Clinical Research |
| Country | United States |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | John Radcliffe Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | King's College London |
| Department | Cardiovascular Division |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Leiden University Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Mario Negri Institute for Pharmacological Research |
| Department | Consorzio Mario Negri Sud (CMNS) |
| Country | Italy |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Mario Negri Institute for Pharmacological Research |
| Department | Consorzio Mario Negri Sud (CMNS) |
| Country | Italy |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Mario Negri Institute for Pharmacological Research |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | McMaster University |
| Department | Population Health Research Institute |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Merck |
| Country | Germany |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Mitsukoshi Health & Welfare Foundation |
| Country | Japan |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Monash University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Monash University |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | National Heart, Lung, and Blood Institute (NHLBI) |
| Country | United States |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Nordic School of Public Health |
| Country | Sweden |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Oslo University Hospital |
| Department | Department of Cardiology |
| Country | Norway |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Oslo University Hospital |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Pfizer Global R & D |
| Country | United States |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Pharma Clinical |
| Country | Israel |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Regeneron Pharmaceuticals, Inc. |
| Country | United States |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Rikshospitalet , Sogsnsavvsveien |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Rosalin Franklin University |
| Department | School of Medicine Rosalin Franklin |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Royal London Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Russells Hall Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Sahlgrenska University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Sahlgrenska University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Sanofi |
| Country | Global |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Sheba Medical Centre |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Sheba Medical Centre |
| Country | Israel |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | St Mary's Hospital, London |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | State University of New York |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Tokai University |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Ulleval University Hospital |
| Country | Norway |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | United States Department of Veterans Affairs |
| Country | United States |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University College Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University College London Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University Hospital, Josef-Schneider-Str 2, Germany |
| Department | Division of Nephrology |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University Hospitals of Cleveland |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Dundee |
| Department | School of Medicine |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Glasgow |
| Department | School of Medicine Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Gothenburg |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Iowa |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of North Texas |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Sydney |
| Department | NHMRC Clinical Trials Centre |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Sydney |
| Department | Sydney Medical School |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Texas |
| Department | School of Public Health Texas |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Texas Health Science Center San Antonio, BrainMap Database |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Texas Southwestern Medical Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Washington |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | University of Wurzburg |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Uppsala University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | VU University Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Cholesterol Treatment Trialists' (CTT) Collaboration |
| Organisation | Wake Forest University |
| Department | Wake Forest School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. McMaster: Inclusion of HOPE-3 trial data (results published in N Engl J Med 2016; 374:2021-2031) in ongoing CTT AE project |
| Impact | The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | American University of Beirut |
| Department | Epidemiology and Population Health Department |
| Country | Lebanon |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Beijing Huilongguan Hospital |
| Country | China |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Cleveland Clinic |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Ecological Institute of Caspian Sea |
| Country | Iran, Islamic Republic of |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Firat University |
| Country | Turkey |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Gastrointestinal & Other Cancers Research Group |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Georgetown University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Harvard University |
| Department | Harvard Medical School |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Hospital of Psychiatry and Psychotherapy, Germany |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Icahn School of Medicine at Mount Sinai |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Johns Hopkins Medicine |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Johns Hopkins University |
| Department | Johns Hopkins Bloomberg School of Public Health |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | King Fahd Hospital, Saudi Arabia |
| Country | Saudi Arabia |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Linkoping University |
| Department | University Medical School Linkoping |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Lund University |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | MAM College of Pharmacology |
| Country | India |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Massachusetts General Hospital |
| Department | Cancer Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Merck |
| Country | Germany |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Mexican Social Security Insitute (IMSS) |
| Country | Mexico |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | New York University |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Northwestern University |
| Department | Feinberg School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Ogun State University Teaching Hospital (OSUTH) |
| Country | Nigeria |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Pfizer Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Queen's Medical Centre |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Rush University Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Sapienza University of Rome |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Sasaki Institute |
| Country | Japan |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Schulthess Clinic |
| Country | Switzerland |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Seoul National University |
| Country | Korea, Republic of |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Statistics Collaborative |
| Country | United States |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Taipei Veterans General Hospital |
| Country | Taiwan, Province of China |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Thrombosis Center of Buenos Aires |
| Country | Argentina |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Tisch Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Toronto General Hospital |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Tri-Services General Hospital |
| Country | Taiwan, Province of China |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Trinity College Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Tripler Medical Army Center, US |
| Country | United States |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Tufts University |
| Department | School of Dental Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Arizona |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Cagliari |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Chieti-Pescara |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Louisville |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Lyon |
| Country | France |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Maryland |
| Department | School of Medicine Maryland |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Ottawa |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Pennsylvania |
| Department | Institute for Translational Medicine and Therapeutics (ITMAT) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Southern California |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Texas |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Toronto |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Utah |
| Department | School of Medicine Utah |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Zagreb |
| Country | Croatia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | University of Zaragoza |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Coxib and traditional NSAID Treatment (CNT) Collaboration |
| Organisation | Vanderbilt University |
| Department | Vanderbilt Medical Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis. |
| Start Year | 2006 |
| Description | Member of Commission on Human Medicine Expert Working Group |
| Organisation | Commission on Human Medicines (CHM) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Member of the Expert Working Group |
| Collaborator Contribution | organising body |
| Impact | n/a |
| Start Year | 2014 |
| Description | New collaboration for MTT Collaboration |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | New collaboration for Marfan Treatment Trialists' Collaboration |
| Collaborator Contribution | New collaboration for Marfan Treatment Trialists' Collaboration |
| Impact | N/A |
| Start Year | 2016 |
| Description | New collaborations for Gastroprotectant Treatment Trialists' Collaboration |
| Organisation | Catholic University Medical School |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Collaborator Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Impact | N/A |
| Start Year | 2016 |
| Description | New collaborations for Gastroprotectant Treatment Trialists' Collaboration |
| Organisation | McMaster University |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Collaborator Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Impact | N/A |
| Start Year | 2016 |
| Description | New collaborations for Gastroprotectant Treatment Trialists' Collaboration |
| Organisation | Miguel Servet University Hospital |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Collaborator Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Impact | N/A |
| Start Year | 2016 |
| Description | New collaborations for Gastroprotectant Treatment Trialists' Collaboration |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Collaborator Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Impact | N/A |
| Start Year | 2016 |
| Description | New collaborations for Gastroprotectant Treatment Trialists' Collaboration |
| Organisation | University Hospitals Birmingham NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Collaborator Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Impact | N/A |
| Start Year | 2016 |
| Description | New collaborations for Gastroprotectant Treatment Trialists' Collaboration |
| Organisation | University of Maryland |
| Department | Department of Physical Therapy and Rehabilitation Science |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Collaborator Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Impact | N/A |
| Start Year | 2016 |
| Description | New collaborations for Gastroprotectant Treatment Trialists' Collaboration |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Collaborator Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Impact | N/A |
| Start Year | 2016 |
| Description | New collaborations for Gastroprotectant Treatment Trialists' Collaboration |
| Organisation | Yale University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Collaborator Contribution | New collaborations on the Gastroprotectant Treatment Trialists' Collaboration |
| Impact | N/A |
| Start Year | 2016 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Boehringer Ingelheim |
| Country | Germany |
| Sector | Private |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Cedars-Sinai Medical Center |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Florey Institute of Neuroscience and Mental Health |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | George Institute for Global Health |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Helsinki University Central Hospital |
| Country | Finland |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Mayo Clinic |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | National Cerebral and Cardiovascular Centre |
| Country | Japan |
| Sector | Public |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Stanford University |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | Technical University of Dresden |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | University Medical Center Hamburg-Eppendorf |
| Department | Department of Neurology |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | University of Alabama at Birmingham |
| Department | School of Medicine |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | University of Edinburgh |
| Department | School of Molecular and Clinical Medicine Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | University of Glasgow |
| Department | School of Medicine Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | University of Melbourne |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | Stroke Thrombolysis Trialists' (STT) Collaboration |
| Organisation | University of Texas |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke. |
| Collaborator Contribution | Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results. |
| Impact | Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability. |
| Start Year | 2011 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Academic Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Antwerp University Hospital |
| Department | Center for Medical Genetics |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | BC Children's Hospital |
| Department | Children's Heart Centre |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Bichat-Claude Bernard Hospital |
| Department | French National Reference Centre for Marfan Syndrome |
| Country | France |
| Sector | Public |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Boston Children's Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Fondazione IRCCS Policlinico San Matteo |
| Country | Italy |
| Sector | Charity/Non Profit |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Johns Hopkins University |
| Department | School of Medicine Johns Hopkins |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | National Heart, Lung, and Blood Institute (NHLBI) |
| Country | United States |
| Sector | Public |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | National Taiwan University |
| Department | Department of Pediatrics |
| Country | Taiwan, Province of China |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | New England Research Institutes Watertown |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Royal Brompton Hospital |
| Department | Clinical Trials and Evaluation Unit |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | University College London |
| Department | Institute of Cardiovascular Science |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | University of East Anglia |
| Department | Faculty of Medicine and Health Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | University of Ghent |
| Department | Centre for Medical Genetics |
| Country | Belgium |
| Sector | Academic/University |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | The Marfan Treatment Trialists' Collaboration |
| Organisation | Vall d'Hebron University Hospital |
| Department | Department of Cardiology |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome. |
| Collaborator Contribution | Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan. |
| Impact | None. |
| Start Year | 2012 |
| Description | American Heart Association Science Symposium |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The American Heart Association annual scientific meeting |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://professional.heart.org/professional/EducationMeetings/MeetingsLiveCME/ScientificSessions/UCM_... |
| Description | Aspirin risks outweigh vascular benefits in healthy: Press release |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Press release resulted in following media coverage: An aspirin a day can do more harm than good: Daily Mail, p.39, 29/05/2009 http://www.dailymail.co.uk/health/article-1189355/An-aspirin-day-harm-good.html Aspirin can put patients at risk: Daily Express, p.9, 29/05/2009 http://www.express.co.uk/posts/view/104077/Aspirin-can-put-patients-at-risk Routine aspirin benefits queried: BBC News Online, 29/05/2009 Do the potential side-effects make aspirin a bitter pill to swallow?: The Times, p.11, 01/06/2009 To highlight to patients and doctors the risks of aspirin in healthy people. |
| Year(s) Of Engagement Activity | 2009 |
| Description | Benefits and safety of statins in lower-risk people: Press release |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Press release resulted in following media coverage: Statins for all over-50s to reduce heart deaths: The Daily Telegraph, front page, 17/05/12 http://www.telegraph.co.uk/health/healthnews/9269027/All-over-50s-should-be-taking-statins.html Why everyone over 50 needs to be taking statins: Daily Mail, p. 3, 17/05/12 http://www.dailymail.co.uk/health/article-2145558/Why-EVERYONE-50-needs-taking-statins-Cholesterol-busting-pills-cut-risk-heart-attack-stroke.html?ito=feeds-newsxml Statin drugs 'can benefit all the over-50s': The Times online, 17/05/12 http://www.thetimes.co.uk/tto/science/medicine/article3417234.ece 'Give statins to everyone over 50': Daily Express, p. 7, 17/05/12 http://www.express.co.uk/posts/view/320619/Give-statins-to-everyone-over-50 Up to 20m people should be prescribed statins, study says: The Guardian, p. 6, 17/05/12 http://www.guardian.co.uk/society/2012/may/17/statins-benefit-millions-heart-health?newsfeed=true Statins 'could benefit the healthy': The Independent, 17/05/12 http://www.independent.co.uk/life-style/health-and-families/health-news/statins-could-benefit-the-healthy-7762347.html Blanket protection: The Sunday Times, 'Briefing', p. 20, 20/05/12 http://www.thesundaytimes.co.uk/sto/comment/regulars/briefing/article1041917.eceStatin therapy may even benefit healthy - study: Channel 4 news online, 17/05/12 http://www.channel4.com/news/statin-therapy-may-even-benefit-healthy-study Statins advised for over 50s: Sky News online, 17/05/12 http://news.sky.com/home/article/16229656 Guideline for statin therapy 'should be reconsidered': ITV News online, 17/05/12 http://www.itv.com/news/update/2012-05-17/guideline-for-statin-therapy-should-be-reconsidered/ Should people with a low risk of heart disease take statins? The Week, 17/05/2012 http://www.theweek.co.uk/health-science/46978/should-people-low-risk-heart-disease-take-statins#ixzz1vCtkclpv Help for hearts: Oxford Mail, In Brief, p.5, 18/05/2012 Statins 'may even help healthy over-50s': NHS Choices website, 17/05/2012 http://www.nhs.uk/news/2012/05may/Pages/statins-may-help-for-healthy-middle-aged-adults.aspx 'Everyone above 50 must take statins regularly': Times of India online, via PTI, 18/05/2012 http://timesofindia.indiatimes.com/home/science/Everyone-above-50-must-take-statins-regularly/articleshow/13240272.cms 'Everyone above 50 should take statins regularly': Financial Express (India), 17/05/2012 http://www.financialexpress.com/news/everyone-over-50-years-should-take-statins-regularly/950659/ All over 50s should be taking statins to avoid heart attack: Newstrack India (via ANI), Unattributed, 17/05/12 http://www.newstrackindia.com/newsdetails/2012/05/17/96-All-over-50s-should-be-taking-statins-to-avoid-heart-attack.html Statins could benefit health of millions: Gulf Times (Qatar), 17/05/2012 Statins 'could benefit the healthy': Kuwait News Agency, Unattributed, 17/05/12 http://www.kuna.net.kw/ArticleDetails.aspx?id=2241098?uage=en BBC News online: NHS 'should consider giving statins to healthy people': 17/05/12 http://www.bbc.co.uk/news/health-18091708 Statins 'could save a lot of lives': Daily Telegraph online (with ITN productions), 17/05/12. Online video report: Jeremy Pearson from the British Heart Foundation discusses the Oxford findings and their implications. http://www.telegraph.co.uk/health/healthnews/9272279/Statins-could-save-a-lot-of-lives.html Radio: BBC Radio 4 Today Programme: 17/05/12, 07:53 http://news.bbc.co.uk/today/hi/today/newsid_9721000/9721511.stm Radio: BBC World Service Newshour: 17/05/2012, 14:19; BBC Radio 2: 17/05/12, 05:18; BBC London: 17/05/2012, 08:19, 10.02; BBC Radio Oxford: 17/05/2012, 14:01; BBC Radio West Midlands: 17/05/2012, 13:14; BBC Radio Sheffield: 17/05/2012, 07:03; BBC Radio Somerset: 17/05/12, 05:51; LBC 97.3: 17/05/12, 03:23, 07.23, 08:57; TV: Sky News Press Preview: 16/05/12, 21:51, 22:43; Sky News: 18/05/12, 00:39 To highlight to patients and doctors the benefits and risks of statins in lower-risk people. |
| Year(s) Of Engagement Activity | 2012 |
| Description | Engagement with Green Templeton College medical students |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Undergraduate students |
| Results and Impact | Presentation about meta-analyses conducted at CTSU |
| Year(s) Of Engagement Activity | 2016 |
| Description | European Society of Cardiology |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The European Society of Cardiology Congress for 2016, held in Rome |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.eurolink-tours.com/2016/esc/ |
| Description | Faculty of Pharmaceutical Medicine Curriculum and Assessment Working Group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Member of Faculty of Pharmaceutical Medicine Curriculum and Assessment Working Group |
| Year(s) Of Engagement Activity | 2019 |
| Description | Faculty of Pharmaceutical Medicine Curriculum and Assessment Working Group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Faculty of Pharmaceutical Medicine Curriculum and Assessment Working Group (re. process of writing a new curriculum for pharmaceutical medicine specialty training). This curriculum will include a set of specialty-specific Capabilities in Practice, together with the GMC's Generic Professional Capabilities. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Freeland School visit |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | • Interactive game aimed at children to explain what data is and its different types hosted by the VOG Research Team (note : this is being developed further by them going to Freeland Primary School in March 2019 for a full day to deliver this game to all year groups). |
| Year(s) Of Engagement Activity | 2019 |
| Description | IF Science Oxford |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The group undertook public engagement activities at the IF Oxford Science Festival |
| Year(s) Of Engagement Activity | 2019 |
| Description | Lecture to Abingdon ATOM science festival |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Gave a lecture about my owrk: Treatment of vascular disease; preventing heart disease and strokes |
| Year(s) Of Engagement Activity | 2015 |
| Description | Media coverage |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Media exposure as a result of the scientific paper published that examined the benefits of statins to women. Coverage was international and included Reuters, Science Daily, Medscape and national newspapers. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Merits of considering more extensive use of statins: Press release |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Press release resulted in following media coverage: Give statins to all over-50s: Daily Mail, p. 1, 29/08/12 http://www.dailymail.co.uk/health/article-2194892/All-50s-statins-regardless-health-history-says-Oxford-professor.html Statins fear is 'putting patient's health at risk', researchers say: Daily Telegraph, p. 1, 29/08/12 http://www.telegraph.co.uk/health/healthnews/9504753/Statins-fear-is-putting-patients-health-at-risk-researchers-say.html Heart drugs for all over-50s call: Daily Mirror, p. 16, 29/08/12 Give cholesterol-busting statins to all over-50s: Daily Express, p. 11, 29/08/12 http://www.express.co.uk/posts/view/342728/-Cholesterol-busting-statins-should-be-given-to-ALL-over-50s- Statin 'for everyone over 50': The Sun, p. 20, 29/08/12 Oxford professor re-ignites statins row: The Times online, 29/08/12 http://www.thetimes.co.uk/tto/health/news/article3521615.ece Health expert says statins should be taken by everyone over 50, even the healthy: The Herald Sun online (Australia), 29/08/12 http://www.heraldsun.com.au/news/national/health-expert-says-statins-should-be-taken-by-everyone-over-50-even-the-healthy/story-fndo471r-1226461088762 TV: ITV 1 Daybreak: 29/08/12, 06:05; BBC News: 28/08/12, 23:27; ITV 1 South Meridian Tonight: 29/08/12, 6.08pm; BBC News Channel: 29/08/12, 11.27pm Radio: BBC Radio Wales Good Morning Wales: 29/08/12, 06:18; BBC Radio Northampton: 29/08/12, 06:13; BBC Radio Foyle: 29/08/12, 1.56pm; BBC Radio Leeds: 29/08/12, 10.36am To highlight to doctors and the public the merits of more extensive use of statins. |
| Year(s) Of Engagement Activity | 2012 |
| Description | Merits of more intensive use of statins: Press release |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Press release resulted in the following media coverage: More potent statins 'could save thousands every year': The Daily Telegraph, p. 1, 09/11/10 http://www.telegraph.co.uk/health/8117635/More-potent-statins-could-save-thousands.html New wonder statin 'could save thousands' at risk of heart attacks or strokes: Daily Mail, 09/11/2010 http://www.dailymail.co.uk/health/article-1327943/New-wonder-statin-save-thousands-risk-heart-attacks-strokes.html?ito=feeds-newsxml Statin is new wonder drug: Daily Express, p. 1, 09/11/10 http://www.dailyexpress.co.uk/posts/view/210424 Aggressive use of statins further cuts cardio risk: study: Independent, 10/11/10 http://www.independent.co.uk/life-style/health-and-families/aggressive-use-of-statins-further-cuts-cardio-risk-study-2129947.html Stronger statins 'could save lives': Daily Mirror, 09/11/10 http://www.mirror.co.uk/news/latest/2010/11/09/stronger-statins-could-save-lives-115875-22703591/ Statin increase 'will save lives': BBC News Online, 09/11/2010 http://www.bbc.co.uk/news/health-11712569 Higher Dose Statins Could Save Lives: Sky News Online, 09/11/2010 http://news.sky.com/skynews/Home/UK-News/Higher-Dose-Statins-Could-Save-Lives-According-To-Report-By-UK-And-Australian-Scientists/Article/201011215797761?lpos=UK_News_First_Home_Page_Feature_Teaser_Region_0&lid=ARTICLE_15797761_Higher_Dose_Statins_Could_Save_Lives_According_To_Report_By_UK_And_Australian_Scientists Aggressive statins use cuts heart risk: Sydney Morning Herald, 09/11/10 http://news.smh.com.au/breaking-news-world/aggressive-statins-use-cuts-heart-risk-20101109-17l1q.html Higher Statin Doses Linked to Fewer Heart Attacks, Stroke: US News & World Report, HealthDay blog, 09/11/10 http://health.usnews.com/health-news/diet-fitness/heart/articles/2010/11/09/higher-statin-doses-linked-to-fewer-heart-attacks-stroke.html Aggressive use of statins further cuts cardio risk: Star (Malaysia), p. 38, 10/11/10 Radio: BBC Radio 5 Up all night, 09/11/10, 01:51am; BBC Radio Oxford, 09/11/10, 11.48am http://www.bbc.co.uk/iplayer/episode/p00by2cc/Louisa_Hannan_09_11_2010/ To highlight amongst doctors and patients the benefits of more intensive cholesterol lowering with statins. |
| Year(s) Of Engagement Activity | 2012 |
| Description | NDPH Participant Panel |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Updated the NDPH Public Advisory Panel (formerly Participany Panel) about the status and progress of meta analyses |
| Year(s) Of Engagement Activity | 2019 |
| Description | NDPH participant panel |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Presentation of Cholesterol Treatment Trialists' Collaboration (CTT) and Marfan Treatment Trialists' Collaboration (MTT) to the Nuffield Department of Population Health Participant Panel |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.ctsu.ox.ac.uk/research/participant-panel |
| Description | No benefit from lowering homocysteine: Press release |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Press release resulted in following media coverage: Regimens: Lower Homocysteine and Heart Risk: New York Times online, 28/06/10 http://www.nytimes.com/2010/06/29/health/research/29regi.html?scp=1&sq=jane%20armitage&st=cse More Evidence That B Vitamins Alone Won't Counter Heart Risks: BusinessWeek, 22/06/2010? Study: Folic Acid, B12 Don't Lower Heart Disease Risks: TIME, 22/06/2010? http://www.time.com/time/health/article/0,8599,1998885,00.html?xid=rss-topstories Study: Folic Acid Doesn't Cut Heart-Attack Risk: Newsweek, 22/06/2010? http://www.newsweek.com/2010/06/22/observe-and-report.html SEARCH published: No CV benefit on reducing homocysteine: TheHeart.Org, 22/06/2010? Is new gene analysis the final chapter in the homocysteine saga? TheHeart.org, 21/02/2012 More Doubt on Link Between a Blood Chemical and Heart Disease: MSN Health (USA, via HealthDay newswire), 21/02/2012 More Doubt on Link Between a Blood Chemical and Heart Disease: DoctorsLounge (USA, via HealthDay newswire), 21/02/2012 http://www.doctorslounge.com/index.php/news/hd/26930 To clearly demonstrate to doctors and patients that homocysteine was not effective in reducing heart disease risk. |
| Year(s) Of Engagement Activity | 2010 |
| Description | Oxford Open Doors 2018 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Open day for the general public, with talks and interactive activities. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Oxford Open Doors 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Took part in the 2019 Oxford Open Doors public engagement event on Saturday 14 September |
| Year(s) Of Engagement Activity | 2019 |
| Description | Press release: Common painkillers increase heart attack risk |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Media coverage: http://www.wired-gov.net/wg/wg-news-1.nsf/0/2993B5F1662159E780257B7C0043B5D0?OpenDocument http://www.pharmatimes.com/Article/13-05-31/Long_term_painkiller_use_linked_to_heart_risk.aspx http://www.bbc.co.uk/mundo/noticias/2013/05/130530_salud_analgesico_riesgo_gtg.shtml http://www.midsussextimes.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.harboroughmail.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.bournelocal.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.louthleader.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.fenlandcitizen.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.cotswoldjournal.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.bucksherald.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.wscountytimes.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.tringtoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.leightonbuzzardonline.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.westsussextoday.co.uk/news/regional/study-in-painkiller-dosage-warning-1-5143606 http://www.biggleswadetoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.thametoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.granthamjournal.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.rugbyadvertiser.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.bostonstandard.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.haylingtoday.co.uk/news/regional/study-in-painkiller-dosage-warning-1-5143606 http://www.lutterworthmail.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.thisischeshire.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.witneygazette.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.meltontimes.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.herefordtimes.com/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.hemeltoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.hastingsobserver.co.uk/news/regional-news/study-in-painkiller-dosage-warning-1-5143606 http://www.lynnnews.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.confused.com/health-insurance/news/study-in-painkiller-dosage-warning-2571 http://www.bognor.co.uk/news/regional/study-in-painkiller-dosage-warning-1-5143606 http://www.dissexpress.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.lutontoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.yorkpress.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.kenilworthweeklynews.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.banburyguardian.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.portsmouth.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.suffolkfreepress.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.dunstabletoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.wandsworthguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.burytimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.eastbourneherald.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.dudleynews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.miltonkeynes.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.leamingtoncourier.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.buryfreepress.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.sleafordstandard.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.buckinghamtoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.marketrasenmail.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.crawleyobserver.co.uk/news/regional/study-in-painkiller-dosage-warning-1-5143606 http://www.rutland-times.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.cravenherald.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.skegnessstandard.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.droitwichadvertiser.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.bedfordtoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.newmarketjournal.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.congletonguardian.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.daventryexpress.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.hillingdontimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.peterboroughtoday.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.borehamwoodtimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.petersfieldpost.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.horncastlenews.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.warwickcourier.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.ealingtimes.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.thelancasterandmorecambecitizen.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.hertfordshiremercury.co.uk/Hertfordshire/National-News/Study-in-painkiller-dosage-warning-2-7455347.xnf http://www.haverhillecho.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.spaldingtoday.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.ellesmereportpioneer.co.uk/ellesmere-port-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-55940-33403855/ http://icburton.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403719%26siteid=82449-name_page.html http://www.formbytimes.co.uk/news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-66401-33403807/ http://www.bedfordshire-news.co.uk/News/UK-and-world-news/Study-in-painkiller-dosage-warning-1-7455347.xnf http://www.falmouthpacket.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.harlowstar.co.uk/News/National-News/Study-in-painkiller-dosage-warning-1-7455347.xnf http://icwalsall.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403839%26siteid=60240-name_page.html http://www.theadvertisergroup.co.uk/Daily-News/National-News/Study-in-painkiller-dosage-warning-2-7455347.xnf http://www.solihullnews.net/news/uk-news/2013/05/30/study-in-painkiller-dosage-warning-105074-33403583/ http://www.littlehamptongazette.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.northamptonchron.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.crewechronicle.co.uk/crewe-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-96135-33403631/ http://www.chichester.co.uk/news/national/study-in-painkiller-dosage-warning-1-5143422 http://www.southportvisiter.co.uk/southport-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-101022-33403599/ http://www.runcornandwidnesweeklynews.co.uk/runcorn-widnes-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-55368-33403863/ http://www.hertsandessexobserver.co.uk/News/National-News/Study-in-painkiller-dosage-warning-2-7455347.xnf http://www.wirralnews.co.uk/wirral-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-80491-33403759/ http://www.harrowobserver.co.uk/west-london-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-116451-33403503/ http://icsuttoncoldfield.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403887%26siteid=52630-name_page.html http://www.osadvertiser.co.uk/news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-80904-33403743/ http://www.uxbridgegazette.co.uk/west-london-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-113046-33403527/ http://icwolverhampton.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403639%26siteid=94950-name_page.html http://www.crosbyherald.co.uk/news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-68459-33403791/ http://www.examiner.co.uk/news/national-news/2013/05/30/study-in-painkiller-dosage-warning-86081-33403703/ http://www.fulhamchronicle.co.uk/fulham-and-hammersmith-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-82029-33403735/ http://www.chesterchronicle.co.uk/chester-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-59067-33403847/ http://www.enfieldindependent.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.ealinggazette.co.uk/ealing-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-64767-33403815/ http://www.blackburncitizen.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.mkweb.co.uk/News/UK-and-World-News/Study-in-painkiller-dosage-warning-2-7455347.xnf http://www.liverpooldailypost.co.uk/liverpool-news/uk-world-news/2013/05/30/study-in-painkiller-dosage-warning-99623-33403607/ http://iccheshireonline.icnetwork.co.uk/0100news/0300nationalnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403927%26siteid=50020-name_page.html http://www.buckinghamshireadvertiser.co.uk/south-buckinghamshire-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-82398-33403727/ http://www.loughboroughecho.net/news/national-news/2013/05/30/study-in-painkiller-dosage-warning-73871-33403783/ http://www.talktalk.co.uk/news/uk/article/study-in-painkiller-dosage-warning/89834/ http://www.standard.co.uk/panewsfeeds/study-in-painkiller-dosage-warning-8636891.html http://www.buckinghamshireexaminer.co.uk/south-bucks-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-114018-33403511/ http://www.chelmsfordweeklynews.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.express.co.uk/news/uk/403637/Study-in-painkiller-dosage-warning http://icsolihull.icnetwork.co.uk/news/national/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403663%26siteid=91411-name_page.html http://www.belfasttelegraph.co.uk/news/local-national/uk/study-in-painkiller-dosage-warning-29307237.html http://www.yeovilexpress.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.romseyadvertiser.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.thurrockgazette.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.durhamtimes.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.thisishampshire.net/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.malverngazette.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.brentwoodweeklynews.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.kidderminstershuttle.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.creweguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.watfordobserver.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.southwalesargus.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.thewestmorlandgazette.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.thisisoxfordshire.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.barryanddistrictnews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.banburycake.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.chorleycitizen.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.gazetteandherald.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.southendstandard.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.stalbansreview.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.newsshopper.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.wirralglobe.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.winsfordguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.middlewichguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.thisislocallondon.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.thenorthernecho.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.ludlowadvertiser.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.boatingcornwall.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.prestoncitizen.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/?ref=nt http://www.eveshamjournal.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.businessdorset.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.northwichguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.sthelensstar.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.dailyecho.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.westerntelegraph.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.southwestfarmer.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.kingstonguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.heraldseries.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/?ref=nt http://www.thisislancashire.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.wiltsglosstandard.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.walesfarmer.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.maldonandburnhamstandard.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.theboltonnews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.wiltshirebusinessonline.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.bridportnews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.bournemouthecho.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.somersetcountygazette.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.lancashiretelegraph.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.thisisthewestcountry.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.gazetteherald.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.croydonguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.stourbridgenews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.theargus.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.oxfordmail.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.harrowtimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.basingstokegazette.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.bridgwatermercury.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.burnleycitizen.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.warringtonguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.leighjournal.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.oxfordtimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.messengernewspapers.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.salisburyjournal.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.knutsfordguardian.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.campaignseries.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.prestwichandwhitefieldguide.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.times-series.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.haringeyindependent.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.ledburyreporter.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.echo-news.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.harwichandmanningtreestandard.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.thisiswiltshire.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.guardian-series.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.stroudnewsandjournal.co.uk/uk_national_news/10451280.Study_in_painkiller_dosage_warning/ http://www.hampshirechronicle.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.basildonrecorder.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://news.uk.msn.com/uk/study-in-painkiller-dosage-warning http://ictamworth.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403687%26siteid=86764-name_page.html http://iclichfield.icnetwork.co.uk/news/natnews/tm_headline=study-in-painkiller-dosage-warning%26method=full%26objectid=33403543%26siteid=108911-name_page.html http://www.shropshirestar.com/news/uk-news/2013/05/30/study-in-painkiller-dosage-warning/ http://www.expressandstar.com/news/uk-news/2013/05/30/study-in-painkiller-dosage-warning/ http://www.hounslowchronicle.co.uk/west-london-news/world-uk-news/2013/05/30/study-in-painkiller-dosage-warning-109642-33403535/ http://www.hinckleytimes.net/news-in-hinckley/uk-news/2013/05/30/study-in-painkiller-dosage-warning-105367-33403575/ http://www.thisisguernsey.com/news/uk-news/2013/05/30/study-in-painkiller-dosage-warning/ http://www.thisisjersey.com/news/uk-news/2013/05/30/study-in-painkiller-dosage-warning/ http://www.stamfordmercury.co.uk/news/national-news/study-in-painkiller-dosage-warning-1-5143422 http://www.sussexexpress.co.uk/news/regional/study-in-painkiller-dosage-warning-1-5143606 http://www.pulsetoday.co.uk/clinical/therapy-areas/pain-relief/consider-switch-to-naproxen-in-arthritis-patients-gps-urged/20003119.article http://www.halesowennews.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.independent.co.uk/life-style/health-and-families/health-news/study-links-common-painkillers-ibuprofen-and-diclofenac-to-increased-risk-of-heart-attack-8636745.html http://www.ageuk.org.uk/latest-news/painkillers-linked-to-heart-disease/ http://www.gponline.com/News/article/1184344/common-painkillers-raise-heart-risks/ http://www.netdoctor.co.uk/interactive/news/common-painkillers-linked-to-heart-attack-risk-id801591952-t116.html http://www.independent.co.uk/life-style/health-and-families/health-news/study-links-overthecounter-painkillers-to-increased-risk-of-heart-attack-8636745.html http://www.medicalnewstoday.com/articles/261183.php http://www.bioportfolio.com/news/article/1483535/Painkillers-Slightly-Increase-Heart-Risk.html http://www.arthritisresearchuk.org/news/general-news/2013/may/some-nsaids-linked-to-small-but-significant-increase-in-heart-attack-risk.aspx http://www.bioportfolio.com/news/article/1483943/Some-NSAIDs-linked-to-small-but-significant-increase-in-heart-attack-risk.html http://www.noodls.com/viewNoodl/18803229/university-of-oxford-/small-increase-in-heart-risk-from-common-painkillers http://www.ox.ac.uk/media/news_stories/2013/130530.html http://www.express.co.uk/news/health/403652/Most-arthritis-victims-need-not-worry-about-painkiller-risks http://www.guardian.co.uk/science/2013/may/30/painkillers-heart-attack-risk-study http://www.pharmaceutical-int.com/news/painkillers-found-to-increase-heart-problems.html http://www.bbc.co.uk/news/health-22713613 http://www.bbc.co.uk/indonesia/majalah/2013/05/130529_iptek_obat_jantung.shtml http://www.dailystar.co.uk/latestnews/view/317404/Study-in-painkiller-dosage-warning/ http://www.heraldscotland.com/news/health/painkiller-use-linked-to-bigger-risk-of-heart-attack.21212962 http://www.wiltshiretimes.co.uk/news/national/news/10451280.Study_in_painkiller_dosage_warning/ http://www.itv.com/news/update/2013-05-30/professor-risks-are-relative-to-medical-background/ http://www.huffingtonpost.co.uk/2013/05/30/health-high-doses-painkillers-heart-risk_n_3356911.html http://www.dailymail.co.uk/health/article-2333067/Painkillers-taken-millions-increase-heart-risk-Prolonged-use-leads-significant-danger.html?ico=home%5Eheadlines http://www.mailonsunday.co.uk/health/article-2333067/Painkillers-taken-millions-increase-heart-risk-Prolonged-use-leads-significant-danger.html http://www.manchesterwired.co.uk/news.php/1486945-Common-painkillers-pose-heart-risk http://www.ukwirednews.com/news.php/1486945-Common-painkillers-pose-heart-risk http://www.bbc.co.uk/news/health-22694858 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61128-9/fulltext http://uk.reuters.com/article/2013/05/29/us-painkillers-risks-idUKBRE94S1FV20130529 http://www.yorkshirepost.co.uk/news/at-a-glance/general-news/high-painkiller-doses-found-to-raise-risk-of-heart-attack-or-stroke-1-5721318 http://metro.co.uk/2013/05/30/painkillers-may-increase-risk-of-heart-attacks-strokes-and-death-3817327/ http://www.independent.co.uk/life-style/health-and-families/health-news/study-links-painkillers-to-increased-risk-of-heart-attack-8636745.html http://www.express.co.uk/news/health/403581/Heart-risks-for-high-dose-users-of-painkillers http://www.express.co.uk/news/health/403576/Why-Ibuprofen-report-is-good-news http://source.meltwaternews.com/tt/ft.com_all/article.php?which=20130529_780_5303 http://www.telegraph.co.uk/health/healthnews/10087871/Painkiller-taken-for-arthritis-is-heart-risk.html http://medicalxpress.com/news/2013-05-meta-analysis-common-painkillers-heart-problems.html Increased public awareness of the hazards of common painkillers. |
| Year(s) Of Engagement Activity | 2013 |
| Description | Press release: Meta-analysis shows that alteplase given promptly after stroke reduces long-term disability |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Media coverage: http://www.femtomedicine.com/prompt-administration-of-alteplase-treatment-reduces-disability-in-stroke-patients/ http://www.femtomedicine.com/alteplase-given-promptly-after-stroke-reduces-long-term-disability-even-in-older-people-those-with-severe-stroke/ http://www.femtomedicine.com/the-lancet-meta-analysis-shows-that-alteplase-given-promptly-after-stroke/ http://www.hospitaldr.co.uk/blogs/our-news/centralising-stroke-services-can-cut-deaths http://medicalxpress.com/news/2014-08-meta-analysis-alteplase-promptly-long-term-disability.html http://www.medicalnewstoday.com/releases/280587.php http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60584-5/fulltext None. |
| Year(s) Of Engagement Activity | 2014 |
| Description | Science Media Centre Expert Panel |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Press conference to share results of the effects of statins on the elderly: • In relation to CTT elderly paper (see: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31942-1/fulltext); attended by Colin Baigent and Boby Mihaylova; see: https://www.sciencemediacentre.org/expert-reaction-to-meta-analysis-looking-at-statins-and-cardiovascular-events-in-all-ages/. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Science Media Centre expert reaction briefing re: statins |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | SMC expert reaction briefing to the Lancet paper interpreting the evidence on risk and benefits of statins on 8 September 2016 |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.sciencemediacentre.org/interpreting-the-evidence--on-the-risks-and-benefits-of-statins/ |
| Description | Science Media Centre press briefing re: statins |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | This was a media briefing to national and international press organisations on the Lancet paper 'Interpretation of the evidence for the efficacy and safety of statin therapy'. It tokk place on 28 June 2016 |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.sciencemediacentre.org/the-perception-of-statins-and-the-impact-of-intense-debate-on-stat... |
| Description | Science Week - Bladon Primary School |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Presentation and engagement around planning experiments during Oxford Science Week |
| Year(s) Of Engagement Activity | 2019 |
| Description | Science Week - Freeland Primary School |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Used data games to engage with primary school during Oxford Science Week |
| Year(s) Of Engagement Activity | 2019 |